peptide research is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Dark chocolate, 70–85% cocoa solids: 80 mg Dark chocolate, 60–69% cocoa solids: 86 mg Dark chocolate, 45–59% cocoa solids: 43 mg Milk chocolate: 20 mg The stimulant effect of chocolate may be due to a combination of theobromine and theophylline, as well as caffeine.
==== Tolerance ==== Tolerance and dependence are risks of chronic benzodiazepine use, and can result in doses within the therapeutic range ceasing to offer meaningful symptomatic relief after prolonged use. Tolerance develops at different rates and to different degrees to the sedative, hypnotic, anticonvulsant, muscle relaxant, and anxiolytic effects of benzodiazepines. A review of benzodiazepine tolerance concluded that it "appears that tolerance develops relatively quickly for the sedative and anticonvulsant actions of benzodiazepines, whereas tolerance to anxiolytic and amnesic effects probably does not develop at all", although the included randomized controlled trial evidence is limited to 22 weeks. A review of clonazepam in the treatment of psychiatric disorders concluded that longitudinal data supports anxiolytic benefit without tolerance during long-term use, including an open-label study finding continued benefit at three years. However, the review concludes that long-term RCT evidence is scant. A study of benzodiazepine sensitivity found that patients treated chronically with alprazolam did not differ from untreated patients in terms of anxiolytic response to diazepam, suggesting a lack of anxiolytic tolerance. However, controversy remains regarding tolerance to anxiolytic effects, with some publications reporting that there is little evidence of continued efficacy beyond 4–6 months or that dependence phenomena are common.
The Allan Hills meteorite, the first to be identified on Earth as having come from the Moon, was discovered in the Transantarctic Mountains in Antarctica by John Schutt and Ian Whillans during the international ANSMET (Antarctic Search for Meteorites) expedition. The meteorite's mass was 31.4 grams (1.11 oz), slightly more than one ounce. Although the lunar meteorite Yamato 791197 had been found on November 20, 1979, it would not be identified as such until 1984. In 1996, examination of the The collapse of a swinging bridge over the Guaíra Falls waterfall killed 32 tourists in Brazil, on the border of Brazil and Paraguay near Guaira, while they were seeking a close view of the waterfall. Those killed fell from a height of 120 feet (37 m) and drowned in the Paraná River. Survivors said that some people on the bridge had been swinging it when the supportive cables snapped.
Sources: en.wikipedia.org
=== Philanthropy === Pfizer sponsors the Royal Society Pfizer Award and The Pfizer Award. In 2022, Pfizer launched the "An Accord for a Healthier World" initiative, which provides Pfizer's medicines and vaccines to 45 lower-income countries on a not-for-profit basis. Notable organizations to which Pfizer has provided funding include the Institute for Advanced Study, University of Toronto, and member of the President's Circle. University of Washington, Habitat for Humanity, Human Rights Campaign, National Women's Law Center, Share Our Strength, WaterAid, National Geographic, National Geographic Society, 94th Academy Awards, National Press Foundation, 19 to Zero, American Society of Hematology, Canadian Cancer Society, Canadian Paediatric Society, Endocrine Society, and European Society of Cardiology. Notable professional associations to which Pfizer has contributed include American Statistical Association, Canadian Association of Emergency Physicians, Canadian Medical Association, Canadian Pharmacists Association, Canadian Pharmacists Journal, Canadian Public Health Association, Ontario Medical Association, Centre for Addiction and Mental Health, Dana–Farber Cancer Institute, Hospital for Sick Children (SickKids), North Bay Regional Health Center, Princess Margaret Cancer Centre, Scarborough Health Network, Sinai Health Foundation, including Mount Sinai Hospital, Bridgepoint Active Healthcare, and the Lunenfeld-Tanenbaum Research Institute, Sunnybrook Health Sciences Centre – Donor.
== Career == Eaton spent his academic career within the Department of Environmental and Occupational Health Sciences (DEOHS) at the University of Washington School of Public Health. He served as the Director of the UW Toxicology Program from 1986 to 1991. From 1995 to 2015, he led the National Institute of Environmental Health Sciences (NIEHS) Core Center as the founding director of the Center for Ecogenetics and Environmental Health (CEEH). In university-wide administration, Eaton served as Associate Dean for Research in the School of Public Health and Community Medicine from 1999 to 2005. He served as Associate Vice Provost for Research from 2006 to 2013, Interim Vice Provost for Research from 2010 to 2011, and Dean and Vice Provost of The Graduate School from 2013 until 2018. He retired as Professor Emeritus in 2019.
Boodikka appears in Green Lantern: First Flight, voiced by Tricia Helfer. This version is an ally of Sinestro who is later killed in a fight with Hal Jordan and Kilowog. Boodikka makes a cameo appearance in Green Lantern: Emerald Knights, voiced again by Grey DeLisle. Boodikka makes a cameo appearance in Green Lantern (2011).
Particular kinds of aquaculture include fish farming, shrimp farming, oyster farming, mariculture, pisciculture, algaculture (such as seaweed farming), and the cultivation of ornamental fish. Particular methods include aquaponics and integrated multi-trophic aquaculture, both of which integrate fish farming and aquatic plant farming. The FAO describes aquaculture as one of the industries most directly affected by climate change and its impacts. Some forms of aquaculture have negative impacts on the environment, such as through nutrient pollution or disease transfer to wild populations.
Sources: en.wikipedia.org
=== Sham acupuncture and research === It is difficult but not impossible to design rigorous research trials for acupuncture. Due to acupuncture's invasive nature, one of the major challenges in efficacy research is in the design of an appropriate placebo control group. For efficacy studies to determine whether acupuncture has specific effects, "sham" forms of acupuncture where the patient, practitioner, and analyst are blinded seem the most acceptable approach. Sham acupuncture uses non-penetrating needles or needling at non-acupuncture points, e.g. inserting needles on meridians not related to the specific condition being studied, or in places not associated with meridians. The under-performance of acupuncture in such trials may indicate that therapeutic effects are due entirely to non-specific effects, or that the sham treatments are not inert, or that systematic protocols yield less than optimal treatment. A 2014 review in Nature Reviews Cancer found that "contrary to the claimed mechanism of redirecting the flow of qi through meridians, researchers usually find that it generally does not matter where the needles are inserted, how often (that is, no dose-response effect is observed), or even if needles are actually inserted.
Haycocknema perplexum are parasitic nematodes which reside in tissue under the skin or in blood vessels. The origin of their natural host is unknown. This group comprises 8% of nematode species affecting vertebrates. Clinical symptoms of haycocknema perplexum include eosinophilia and high levels of creatine kinase. While rare, with only thirteen documented cases, all originating in Australia, this parasite can become fatal if left untreated due to muscular dystrophy of the respiratory system. The first case was documented in 1998, and no cases in non-human animals have been reported as of 2022. Only one documented death from complications of infection has been recorded. The current treatment for the parasite is 400 mg of Albendazole. The broad-spectrum anthelmintic drug can treat diseases by impairing the parasite's ability to absorb glucose, resulting in its death.
V. A. Shiva Ayyadurai (born Vellayappa Ayyadurai Shiva on December 2, 1963) is an American engineer, entrepreneur, and anti-vaccine activist. He has become known for promoting conspiracy theories, pseudoscience, and unfounded medical claims. Ayyadurai holds four degrees from the Massachusetts Institute of Technology (MIT), including a PhD in biological engineering, and is a Fulbright grant recipient. In a 2011 article published by Time, Ayyadurai claimed to have invented email as a teenager; in August 1982, he registered the copyright on an email application he had written, asserting in his copyright filing, "I, personally, feel EMAIL is as sophisticated as any electronic mail system on the market today." Historians strongly dispute this account because email was already in use in the early 1970s. Ayyadurai sued Gawker Media and Techdirt for defamation for disputing his account of inventing email; both lawsuits were settled out of court. Ayyadurai and Techdirt agreed to Techdirt's articles remaining online with a link to Ayyadurai's rebuttal on his own website. Ayyadurai also attracted attention for two reports: the first questioning the working conditions of India's largest scientific agency; the second questioning the safety of genetically modified food, such as soybeans. During the COVID-19 pandemic, Ayyadurai became known for a social media COVID-19 disinformation campaign, spreading conspiracy theories about the cause of COVID-19, promoting unfounded COVID-19 treatments, and campaigning to fire Anthony Fauci for allegedly being a deep state actor.
== Endolithic fungi and algae in marine ecosystems == Although it is possible that endolithic fungi could play an important role in the health of coral reefs, only limited research has been conducted on the distribution and diversity of marine endolithic fungi. Endolithic fungi have been discovered in shells as early as the year 1889 by Edouard Bornet and Charles Flahault. These two French phycologists specifically provided descriptions for two fungi: Ostracoblabe implexis and Lithopythium gangliiforme. Discovery of endolithic fungi, such as Dodgella priscus and Conchyliastrum, has also been made in the beach sand of Australia by George Zembrowski. Findings have also been made in coral reefs and have been found to be, at times, beneficial to their coral hosts. In the wake of worldwide coral bleaching, studies have suggested that the endolithic algae located in the skeleton of the coral may be aiding the survival of coral species by providing an alternative source of energy. Although the role that endolithic fungi play is important in coral reefs, it is often overlooked because much research is focused on the effects of coral bleaching as well as the relationships between Coelenterate and endosymbiotic Symbiodinia. According to a study done by Astrid Gunther endoliths were also found in the island of Cozumel (Mexico). The endoliths found there not only included algae and fungi but also included cyanobacteria, sponges as well as many other microborers.
extein Any part of an amino acid sequence which is retained within a precursor polypeptide, i.e. not excised by post-translational protein splicing, and is therefore present in the mature protein, analogous to the exons of RNA transcripts. Contrast intein.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.